NervGen Pharma Corp (NGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NervGen Pharma Corp (NGEN) has a cash flow conversion efficiency ratio of 1.808x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.32 Million ≈ $-3.85 Million USD) by net assets (CA$-2.94 Million ≈ $-2.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of NervGen Pharma Corp for the company's overall valuation and market capitalisation.
NervGen Pharma Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NervGen Pharma Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NervGen Pharma Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NervGen Pharma Corp ranked by their cash flow conversion efficiency. See NGEN operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uchi Technologies Bhd
KLSE:7100
|
0.118x |
|
Eimskipafélag Íslands hf
IC:EIM
|
0.017x |
|
Chunbo Co. Ltd
KQ:278280
|
0.001x |
|
Sprott Focus Trust
NASDAQ:FUND
|
N/A |
|
Rapac Communication & Infrastructure Ltd
TA:RPAC
|
-0.017x |
|
Phihong Technology Co Ltd
TW:2457
|
-0.063x |
|
Grieg Seafood ASA
OL:GSF
|
0.038x |
|
Siddhi Acquisition Corp Class A Common stock
NASDAQ:SDHI
|
-0.001x |
Annual Cash Flow Conversion Efficiency for NervGen Pharma Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of NervGen Pharma Corp from 2017 to 2024. View latest NervGen Pharma Corp stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$2.58 Million ≈ $1.86 Million |
CA$-16.84 Million ≈ $-12.18 Million |
-6.536x | -216.26% |
| 2023-12-31 | CA$-2.01 Million ≈ $-1.45 Million |
CA$-11.30 Million ≈ $-8.17 Million |
5.622x | +525.55% |
| 2022-12-31 | CA$13.46 Million ≈ $9.74 Million |
CA$-17.78 Million ≈ $-12.86 Million |
-1.321x | -168.70% |
| 2021-12-31 | CA$16.82 Million ≈ $12.17 Million |
CA$-8.27 Million ≈ $-5.98 Million |
-0.492x | +53.85% |
| 2020-12-31 | CA$5.92 Million ≈ $4.28 Million |
CA$-6.31 Million ≈ $-4.56 Million |
-1.065x | +23.12% |
| 2019-12-31 | CA$5.84 Million ≈ $4.23 Million |
CA$-8.09 Million ≈ $-5.86 Million |
-1.386x | -234.95% |
| 2018-12-31 | CA$2.51 Million ≈ $1.82 Million |
CA$-1.04 Million ≈ $-752.38K |
-0.414x | -100.47% |
| 2017-12-31 | CA$-11.81K ≈ $-8.55K |
CA$-1.04 Million ≈ $-752.38K |
88.045x | -- |
About NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more